drugset / Trial / NCT01921907

Evaluation of a Topical Treatment for Actinic Keratosis

NCT01921907 ↗

Phase 2 Completed 52 enrolled Assuta Hospital Systems
RandomizedParallel-groupDouble-blindTreatment

Summary

A topical treatment applied twice daily for 4 weeks to induce disappearance of facial actinic keratosis (AK). First 4 weeks treatment (visit 1, 2 and 3 at 0,2 an 4 weeks) treated as a double blind parallel study. From weeks 4 to 7 (visit 3 to visit 4) all patients to be treated by the active component.

Timeline

Start
2013-07
Primary completion
2014-06
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AD17137 Unknown — Topical

Indications